uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Investigational drugs for neuroendocrine tumours
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Internal Medicine. (Kjell Öberg)
2009 (English)In: Expert Opinion on Investigational Drugs, ISSN 1354-3784, Vol. 18, no 5, 601-608 p.Article, review/survey (Refereed) Published
Abstract [en]

Background: Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus. The majority are malignant. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. Objective: To review and discuss new treatments for patients with metastatic NETs. Method: Review of the published literature during the last 5 years on treatment of patients with NETs. Results/conclusion: Several new drugs with various mechanisms of action including cytotoxic drugs, tyrosine kinase receptor inhibitors and antiangiogenic drugs as well as radiolabelled substances have been introduced during recent years. Many of these compounds have shown promising results in patients with NETs.

Place, publisher, year, edition, pages
2009. Vol. 18, no 5, 601-608 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-140812DOI: 10.1517/13543780902850432ISI: 000266191900005PubMedID: 19388877OAI: oai:DiVA.org:uu-140812DiVA: diva2:384437
Available from: 2011-01-10 Created: 2011-01-10 Last updated: 2011-01-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Internal Medicine
In the same journal
Expert Opinion on Investigational Drugs
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 145 hits
ReferencesLink to record
Permanent link

Direct link